Asia Pacific Influenza Vaccines Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2028 – COVID-19 Impact and Regional Analysis ­– by Vaccine Type (Quadrivalent Vaccines and Trivalent Vaccines), Virus Type (Influenza Virus Type A and Influenza Virus Type B), Technology (Egg-based and Cell-based), Route of Administration (Injection and Nasal Spray), and Target Group (Infants, Children, Adults, and Elderly People) 

No. of Pages: 166    |    Report Code: BMIRE00027310    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Asia Pacific Influenza Vaccines Market
Free Sample Buy Now

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. Asia Pacific Influenza Vaccines Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. Asia Pacific Influenza Vaccines Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1 Increase in flu outbreaks and seasonal epidemics
  • 5.1.2 Rising awareness and vaccination campaigns
5.2 Market Opportunities
  • 5.2.1 Expansion in vaccination programs
  • 5.2.2 Rise in government-funded vaccination initiatives
5.3 Future Trends
  • 5.3.1 Development of universal flu vaccines
  • 5.3.2 Growth in needle-free vaccine technologies
5.4 Impact of Drivers and Restraints

6. Asia Pacific Influenza Vaccines Market Regional Analysis

6.1 Asia Pacific Influenza Vaccines Market Overview
6.2 Asia Pacific Influenza Vaccines Market Revenue 2020-2028 (US$ Million)
6.3 Asia Pacific Influenza Vaccines Market Forecast Analysis

7. Asia Pacific Influenza Vaccines Market Analysis – by Vaccine Type

7.1 Quadrivalent Vaccines and Trivalent Vaccines
  • 7.1.1 Overview
  • 7.1.2 Quadrivalent Vaccines and Trivalent Vaccines: Asia Pacific Influenza Vaccines Market – Revenue and Forecast to 2031 (US$ Million)

8. Asia Pacific Influenza Vaccines Market Analysis – by Virus Type

8.1 Influenza Virus Type A and Influenza Virus Type B
  • 8.1.1 Overview
  • 8.1.2 Influenza Virus Type A and Influenza Virus Type B: Asia Pacific Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)

9. Asia Pacific Influenza Vaccines Market Analysis – by Technology

9.1 Egg-based and Cell-based
  • 9.1.1 Overview
  • 9.1.2 Influenza Virus Type A and Influenza Virus Type B: Asia Pacific Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)

10. Asia Pacific Influenza Vaccines Market – Asia-Pacific Analysis

10.1 Asia-Pacific
  • 10.1.1 Asia Pacific Influenza Vaccines Market Breakdown, by Key Country, 2023 and 2028 (%)
  • 10.1.1.1 Asia Pacific Influenza Vaccines Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 China: Asia Pacific Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.1.1 China: Asia Pacific Influenza Vaccines Market Breakdown, by Vaccine Type
    • 10.1.1.1.2 China: Asia Pacific Influenza Vaccines Market Breakdown, by Virus Type
    • 10.1.1.1.3 China: Asia Pacific Influenza Vaccines Market Breakdown, by Technology
  • 10.1.1.2 India: Asia Pacific Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.2.1 India: Asia Pacific Influenza Vaccines Market Breakdown, by Vaccine Type
    • 10.1.1.2.2 India: Asia Pacific Influenza Vaccines Market Breakdown, by Virus Type
    • 10.1.1.2.3 India: Asia Pacific Influenza Vaccines Market Breakdown, by Technology
  • 10.1.1.3 Japan: Asia Pacific Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.3.1 Japan: Asia Pacific Influenza Vaccines Market Breakdown, by Vaccine Type
    • 10.1.1.3.2 Japan: Asia Pacific Influenza Vaccines Market Breakdown, by Virus Type
    • 10.1.1.3.3 Japan: Asia Pacific Influenza Vaccines Market Breakdown, by Technology
  • 10.1.1.4 Australia: Asia Pacific Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.4.1 Australia: Asia Pacific Influenza Vaccines Market Breakdown, by Vaccine Type
    • 10.1.1.4.2 Australia: Asia Pacific Influenza Vaccines Market Breakdown, by Virus Type
    • 10.1.1.4.3 Australia: Asia Pacific Influenza Vaccines Market Breakdown, by Technology
  • 10.1.1.5 Rest of Asia-Pacific : Asia Pacific Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.5.1 Rest of Asia-Pacific : Asia Pacific Influenza Vaccines Market Breakdown, by Vaccine Type
    • 10.1.1.5.2 Rest of Asia-Pacific : Asia Pacific Influenza Vaccines Market Breakdown, by Virus Type
    • 10.1.1.5.3 Rest of Asia-Pacific : Asia Pacific Influenza Vaccines Market Breakdown, by Technology

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. Asia Pacific Influenza Vaccines Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 AstraZeneca
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 Emergent BioSolutions Inc.
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 GlaxoSmithKline plc.
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 Hualan Biological Engineering Inc.
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 Mitsubishi Chemical Group Corporation
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 Moderna, Inc.
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 MYLAN N.V.
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 Sanofi
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments
13.9 SEQIRUS
  • 13.9.1 Key Facts
  • 13.9.2 Business Description
  • 13.9.3 Products and Services
  • 13.9.4 Financial Overview
  • 13.9.5 SWOT Analysis
  • 13.9.6 Key Developments
13.10 Serum Institute of India Pvt. Ltd
  • 13.10.1 Key Facts
  • 13.10.2 Business Description
  • 13.10.3 Products and Services
  • 13.10.4 Financial Overview
  • 13.10.5 SWOT Analysis
  • 13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - A Market

  1. AstraZeneca
  2. Emergent BioSolutions Inc.
  3. GlaxoSmithKline plc.
  4. Hualan Biological Engineering Inc.
  5. Mitsubishi Chemical Group Corporation
  6. Moderna, Inc.
  7. MYLAN N.V.
  8. Sanofi
  9. SEQIRUS
  10. Serum Institute of India Pvt. Ltd
asia-pacific-influenza-vaccines-market